» Articles » PMID: 35856336

Association Between Periodontal Disease, Tooth Extraction, and Medication-related Osteonecrosis of the Jaw in Women Receiving Bisphosphonates: A National Cohort-based Study

Overview
Journal J Periodontol
Date 2022 Jul 20
PMID 35856336
Authors
Affiliations
Soon will be listed here.
Abstract

Background: We investigated whether periodontal diseases contribute to the development of medication-related osteonecrosis of the jaw (MRONJ) in addition to tooth extraction, which is a major risk factor for MRONJ occurrence.

Methods: This retrospective, nationwide cohort study was performed using South Korea's National Health Insurance Service database on women aged > 50 years who took bisphosphonates for at least 1 year between 2010 and 2015. MRONJ, periodontal disease, and tooth extraction were defined using the claims data.

Results: Among the 27,168 patients analyzed, the incidence of confirmed MRONJ was significantly higher in the periodontal disease group (0.58%) than in the nonperiodontal disease group (0.31%). While extraction alone showed an increased risk of MRONJ development (hazard ratio [HR] = 1.61, 95% confidence interval [CI]: 0.74-3.52), periodontal disease without tooth extraction also indicated a similar risk (HR = 1.68, 95% CI: 0.86-3.28); when a history of both periodontal disease and tooth extraction was present, the HR significantly increased to 2.55 (95% CI: 1.41-4.64).

Conclusions: The risk of MRONJ increased significantly when tooth extraction was performed in patients diagnosed with periodontal disease; therefore, periodontal diseases should be proactively managed in patients taking bisphosphonates.

Citing Articles

High-dose denosumab (Xgeva®) Associated Medication-Related Osteonecrosis of the Jaws (MRONJ): incidence and clinical characteristics in a retrospective analysis of 1278 patients.

Moon C, Kim H, Park J, Park W, Kim H, Jung Y Support Care Cancer. 2024; 32(12):774.

PMID: 39499349 DOI: 10.1007/s00520-024-08974-6.


Oral and Gingival Crevicular Fluid Biomarkers for Jawbone Turnover Diseases: A Scoping Review.

Fadli N, Abdul Rahman M, Karsani S, Ramli R Diagnostics (Basel). 2024; 14(19).

PMID: 39410587 PMC: 11475764. DOI: 10.3390/diagnostics14192184.


Letter to editor regarding "bone modifying agents in breast cancer patients as adjuvant therapy and prevention of cancer treatment-induced bone loss (CTIBL): Evaluation of risk of medication-related osteonecrosis of the jaw (MRONJ)".

Campisi G, Bedogni A, Saia G, Coppini M, Mauceri R, Fusco V Support Care Cancer. 2024; 32(10):698.

PMID: 39352599 DOI: 10.1007/s00520-024-08891-8.


Medication-related osteonecrosis of the jaw: a retrospective single center study of recurrence-related factors after surgical treatment.

Ruan H, Li M, Zhang Z, Ma H, He Y Clin Oral Investig. 2024; 28(10):549.

PMID: 39317736 PMC: 11422288. DOI: 10.1007/s00784-024-05911-z.


Advances in mechanism and management of bone homeostasis in osteonecrosis: a review article from basic to clinical applications.

Xiang X, He H, He C Int J Surg. 2024; 111(1):1101-1122.

PMID: 39311934 PMC: 11745759. DOI: 10.1097/JS9.0000000000002094.